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Sialidase NEU4 is involved in glioblastoma stem cell
survival
I Silvestri1,6, F Testa1,6, R Zappasodi2, CW Cairo3, Y Zhang3, B Lupo4, R Galli5, M Di Nicola2, B Venerando1 and C Tringali*,1
The human sialidase, NEU4, has emerged as a possible regulator of neuronal differentiation and its overexpression has been
demonstrated to promote the acquisition of a stem cell-like phenotype in neuroblastoma cells. In this paper, we demonstrated
that glioblastoma stem cells (GSCs) isolated from glioblastoma multiforme (GBM) cell lines and patients’ specimens as
neurospheres are specifically marked by the upregulation of NEU4; in contrast, the expression of NEU4 is very low in
non-neurosphere-differentiated GBM cells. We showed that NEU4 silencing by miRNA or a chemical inhibitor of its catalytic
activity triggered key events in GSCs, including (a) the activation of the glycogen synthase kinase 3b, with the consequent
inhibition of Sonic Hedgehog and Wnt/b-catenin signalling pathways; (b) the decrease of the stem cell-like gene expression and
marker signatures, evidenced by the reduction of NANOG, OCT-4, SOX-2, CD133 expression, ganglioside GD3 synthesis, and an
altered protein glycosylation profile; and (c) a significant decrease in GSCs survival. Consistent with this finding, increased
NEU4 activity and expression induced in the more differentiated GBM cells by the NEU4 agonist thymoquinone increased the
expression of OCT-4 and GLI-1. Thus, NEU4 expression and activity appeared to help to determine the molecular signature of
GSCs and to be closely connected with their survival properties. Given the pivotal role played by GSCs in GBM lethality,
our results strongly suggest that NEU4 inhibition could significantly improve current therapies against this tumour.
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Glioblastoma multiforme (GBM) is the most lethal and least
successfully treated brain tumour,1 with a median survival of
15 months.2 Many studies have revealed that GBM includes a
heterogeneousmixture of both cancer stem cells that possess
the property of self-renewal, as well as more differentiated
cancer cells.3,4 GBM stem cells (glioblastoma stem cells
(GSCs)) are believed to be responsible for GBM develop-
ment, progression, recurrence, and therapeutic resistance.5,6
GSCs share the expression of many markers, such as CD133
and nestin (NES),7 and core signalling pathways, such as
Sonic Hedgehog (SHH)-GLI, Notch-1,8 and Wnt/b-catenin,9
with normal neural stem cells. These signalling pathways are
known to sustain the long-term self-renewal and propagation
of GSCs.8,9 To identify GSCs features, recent papers have
focused on the glycosylation status of somemarkers including
CD133.10,11 Furthermore, several glycoprotein markers
involved in the differentiation status of GSCs were identified
through amulti-lectin affinity chromatography and quantitative
glycoproteomics approach.12 Regarding glycolipids, b-series
gangliosides such as GD2 (Klassen et al.13) and GD3
(Yanagisawa et al.14 and Nakatani et al.15) have been
previously demonstrated to be highly expressed in normal
neural stem cells. In mouse neural stem cells, GD3 interacts
with epidermal growth factor receptor (EGFR) stimulating
its downstream signalling to support cell self-renewal
capability.16 During mammalian brain development, the levels
of simple gangliosides, that is, GD3 andGM3, decrease, while
the synthesis of a-series gangliosides (GM1 and GD1a)
increases.17 As the ganglioside pattern of neural stem cells
seems to reflect their undifferentiated status and their self-
renewal ability, it could be hypothesized that GSCs could also
display an altered synthesis of gangliosides. The stage-
specific embryonic antigenic-1 (CD15), a glycosylated epitope
carried by glycoproteins and by glycolipids was associated
with GSCs.18 Sialidases are enzymes critically involved in the
control of protein and lipid glycosylation and altered in
cancer.19–23 Sialidases (EC 3.2.1.18) catalytically remove
sialic acid24 and, among many crucial cell events, in the
nervous system they are involved in neuronal differentiation,
neuritogenesis, and axonal growth.25–27 Among the four
sialidases described so far, that is, NEU1, NEU2, NEU3,
and NEU4, the latter appeared to be intriguingly related to the
fate of neural cells. The level of NEU4 gene expression
decreases during the development of the mouse brain and
during retinoic acid-induced neuronal differentiation.28 More-
over, we previously reported that the NEU4 overexpression
enhances an undifferentiated stem cell-like phenotype and
cell proliferation in human neuroblastoma cells22 and,
recently, it has been demonstrated that mouse neural stem
cells highly express NEU4.29
1Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate (Milan), Italy; 2Medical Oncology Department, Fondazione IRCCS
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; 3Alberta Glycomics Center, Department of Chemistry, University of Alberta, Edmonton, Alberta
T6G 2G2, Canada; 4Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment (IRCC), Candiolo (Torino), Italy and 5Neural Stem Cell Biology
Unit, Division of Regenerative Medicine Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy
*Corresponding author: C Tringali, Department of Medical Biotechnology and Translational Medicine, University of Milan, via F.lli Cervi 93, Segrate Milan 20090, Italy.
Tel: +39 (02) 50330340; Fax: +39 (02) 50330365; E-mail: cristina.tringali@unimi.it
6These authors equally contributed to the work.
Received 15.4.14; revised 08.7.14; accepted 09.7.14; Edited by A Stephanou
Abbreviations: GBM, glioblastoma multiforme; GSC, glioblastoma stem cell; SHH, Sonic Hedgehog; EGFR, epidermal growth factor receptor; PTCH1, protein patched
homolog 1; TQ, thymoquinone; DANA, 2,3-deydro-2-deoxy-N-acetylneuraminic acid; GSK-3b, glycogen synthase kinase 3b
Citation: Cell Death and Disease (2014) 5, e1381; doi:10.1038/cddis.2014.349
& 2014 Macmillan Publishers Limited All rights reserved 2041-4889/14
www.nature.com/cddis
Despite these findings, the role of sialidases in GBM
pathogenesis remains to be firmly established. We first
analysed sialidase expression in GSCs and we identified a
significant increase of NEU4 expression in comparison with
more differentiated GBM cells. Then, through NEU4 silencing
and its chemical inhibition in GSCs, we demonstrated that (a)
NEU4 is connected to the inhibition of glycogen synthase
kinase-3b (GSK-3b) and, therefore, to the activation of the
downstream pathways SHH and Wnt/b-catenin; (b) NEU4
expression is associated with the expression of the transcrip-
tional factors,GLI-1,NANOG,OCT-4, and SOX-2; and (c) the
silencing or chemical inhibition of NEU4 changes the entire
glycosylation pattern of proteins and lipids, making it more
similar to that of differentiated GBM cells and drastically
reduces GSCs survival.
Results
Sialidase NEU4 expression is higher in GSCs isolated
from GBM cell lines than in non-neurospheres differ-
entiated GBM cells. Human GBM cell lines U87MG,
U138MG, and T98G were cultivated in selective medium, for
4 weeks, to promote the enrichment of GSCs, as previously
reported.30 As shown in Figure 1a, after an initial steady phase
of about 4 days, some U87MG and U138MG cells began to
grow in suspension forming typical aggregates, referred to as
neurospheres (U87MG duplication rate: 7 days; U138MG
duplication rate: 14 days) (Figure 1b). We demonstrated that
neurospheres formed by both U87MG and U138MG cells
were highly enriched by GSCs through the evaluation of the
expression of the stem cell markers CD133 (5.6-fold increase in
U87MG cells and 4-fold increase in U138MG cells, after 4
weeks) and nestin (9.5-fold increase in U87MG cells and 1.8-fold
increase in U138MG cells, after 4 weeks) (Figures 1c and d).
After 4 weeks, the expression of these two markers did not
further increase. Moreover, the GSC phenotype was further
confirmed by functional assays of Hoechst 33342 dye
exclusion and self-renewal (serial neurosphere formation)
(data not shown). Instead, T98G cells were not able to survive
in the selective medium, and after 14 days all cells died
(Figure 1a). Accordingly, CD133 and nestin expression did not
significantly increase (Figure 1e), indicating the absence of
GSCs among T98G cells able to survive in these culture
conditions. In parallel, we also determine the expression of
sialidases NEU1, NEU3, and NEU4 in all three GBM cell lines
and in neurospheres isolated from them. The cytosolic
sialidase NEU2 was not expressed. NEU1 and NEU3
expression did not significantly change between U87MG-
adherent cells and GSC-enriched neurospheres, or between
U138MG-adherent cells and GSC-enriched neurospheres.
Instead, NEU4 expression that was scarcely detectable in
U87MG and in U138MG cells, increased by 14-fold comparing
U87MG- and U138MG-adherent cells with the corresponding
GSCs, after 4 weeks in selective medium (Figures 1f and g).
We did not record the increment of NEU4 expression in T98G
cells cultivated in the same selective medium (Figure 1h).
NEU4 silencing impairs U87MG-GSCs survival. To deter-
mine the role of sialidase NEU4 and the significance of its
increase in GSCs, after 4 weeks of culture in selective
medium, GSCs isolated from U87MG cells (referred to as
U-GSCs) were transfected with pcDNA 6.2-GW/EmGFP-miR
carrying a miRNA specifically designed towards NEU4. The
silencing effect was verified by real-time PCR (-60% as NEU4
mRNA expression) (Figure 2a). NEU4 silencing strongly
impaired U-GSC survival: in fact, 6 days after the end of
selection, mock U-GSCs began to grow (þ 25%); instead,
70% of NEU4 silencing U-GSCs (referred to as iNEU4
U-GSCs) died and, after 12 days, almost the 87% of cells
died (Figure 2b). The clonogenic potential was determined
performing limiting dilution assays: neurospheres were readily
formed after 5 days by mock U-GSCs but not by iNEU4
U-GSCs (Figure 2c). Hoechst 33342 staining of mock
U-GSCs and iNEU4 U-GSCs revealed the condensation of
chromatin in iNEU4 U-GSCs, indicating an apoptotic pheno-
type (Figure 2d). The configuration of key proteins involved in
cell cycle control revealed that iNEU4 U-GSCs were mainly
blocked in the G2 phase: in fact, phospho-RB (Ser807/811)
was not detected in contrast to mock U-GSCs, cyclin B1 was
markedly accumulated, and inactive phospho-CDC2 (Tyr15)
decreased (63%) (Po0.01) (Figure 2e). Moreover, we
detected a marked downregulation of activated AKT (45%;
Po0.01) and the appearance of the active fragment derived
from the cleavage of caspase 3 in iNEU4 U-GSCs (Figure 2e),
confirming the inhibition of pro-survival pathways and, instead,
the parallel activation of signalling linked to cell death.
NEU4 silencing reduces the activation of signalling
pathways related to stemness in U87MG-GSCs. Through
the investigation of the molecular pathways altered by NEU4
silencing in GSCs and mainly related to their survival and
maintenance, we identified a 74% decrease of phospho-
glycogen synthase kinase-3b (GSK-3b) (Ser9) (inhibitory
phosphorylation) in iNEU4 U-GSCs (Figure 3a) (Po0.001).
This event was clearly related to many important subsequent
effects: first, we detected a decrease in the mRNA expres-
sion of SHH (82%), protein patched homolog 1 (PTCH1)
(70%), and GLI-1 (41.7%), clearly related to the activation of
SHH pathway, and b-catenin (55.6%) and axin 2 (82%),
clearly related to the activation of Wnt/b-catenin pathway, in
iNEU4 U-GSCs (Figure 3b). Activated GSK-3b is a well-
known inhibitor of both SHH31,32 and Wnt/b-catenin33
signalling pathways. As SHH and Wnt/b-catenin pathways
have a central role in GSCs behaviour by promoting an
embryonic stem cell-like gene expression signature,34,35 we
investigated the expression of the known stem cell markers
NANOG, OCT-4, and SOX-2. As shown in Figure 3c, in
iNEU4 U-GSCs, NANOG expression decreased by 17%,
OCT-4 by 71.5%, and SOX-2 by 42%, confirming the partial
inhibition of the signalling pathways that fuel stem cell
growth. Accordingly, the expression of the stemness marker
CD133 decreased in iNEU4 U-GSCs (30%) (Figure 3c).
Interestingly, also the content of the EGFR, which is usually
constitutively activated in GSCs, decreased in iNEU4
U-GSCs ( 74%; Po0.001) (Figure 3d).
NEU4 silencing alters the sialo-glycoconjugate profile of
U87MG-GSCs. As gangliosides and sialo-glycoproteins
could be potential substrates of NEU4, we investigated
sphingolipid pattern of GSCs after NEU4 silencing. It was
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evaluated by metabolic labelling with [3-3H]sphingosine. After
a 2-h pulse followed by a 24-h chase, a metabolic steady state
was obtained. The ganglioside profile of iNEU4 U-GSCs was
clearly different from that of mock U-GSCs (Figures 4a and b).
The content of all ganglioside, except GM3 and GM2,
decreased in iNEU4 U-GSCs; in particular, GD1a, GD3, and
GM1 underwent a 29, 74, and 55% decrease, respectively
(Figure 4b). It is worth noting that these modifications were
associated with alterations concerning the expression of
GD3 synthase ( 59%) (Figure 4c), which is regulated at a
transcriptional level by Sp1 factors ( 52.3% in iNEU4
U-GSCs) (Figure 4d). Significantly, after NEU4 silencing,
GD3 synthase expression was reduced to the level shown by
more differentiated U87MG cells (Figure 4d).
Among neutral sphingolipids, in iNEU4 U-GSCs, we
detected the decrease of lactosylceramide (LacCer)
( 30%), which is considered a pro-survival sphingolipid,
and the parallel increase of ceramide (Cer) (þ 50%), which is
known as a pro-apoptotic sphingolipid;36 glycosylceramide
(GlcCer) did not change (Figures 4e and f).
Figure 1 NEU4 expression in GBM cell lines and GSCs. (a) Growth curves of U87MG, U138MG, and T98G GBM cells cultivated in DMEM F12 medium plus supplements
for up to 4 weeks. Values are the mean±S.D. of four independent experiments. Significance is based on the Student’s t-test: ***Po0.001 (values compared with that on Day 0).
(b) Microphotographs of representative GBM cells and neurospheres formed by U87MG cells after 4 weeks of culture in the selective medium. Original magnification  20
(Olympus Ix50). (c) Real-time PCR analysis of CD133 and nestin expression in U87MG cells; (d) U138MG cells; (e) T98G cells during for weeks of culture in DMEM F12
medium plus supplements. (f) Real-time PCR analysis of NEU1, NEU3, and NEU4 sialidases expression in U87MG cells; (g) U138MG cells; (h) T98G cells during 4 weeks of
culture in DMEM F12 medium plus supplements. Values are the mean±S.D. of four independent experiments. Significance is based on the Student’s t-test: ***Po0.001
(values compared with starting cell lines)
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We also investigated the a2-3 sialoglycoprotein profile of
mock U-GSCs and iNEU4 U-GSCs (Figure 5a). Overall, the
level of sialylation displayed by iNEU4 U-GSCs appeared to be
reduced in comparison with mock U-GSCs with the exception
of some glycoproteins of B50–60kDa, which showed an
increased content of sialic acid (Figure 5a). As for sphingolipids,
it should be underlined that other enzymes involved in the
sialylation of glycoproteins changed their expression following
NEU4 silencing. Interestingly, a2-3 silayltransferase (ST3GalIII),
which encodes a a2-3 sialyltransferase, was significantly
increased as mRNA expression in U-GSCs than in U87MG
cells (þ 70%), but decreased in iNEU4 U-GSCs ( 70% in
comparison with mock U-GSCs) reverting to the levels found
in more differentiated U87MG cells (Figure 5b).
Chemical inhibition or activation of NEU4 changes the
expression of stem cell-like genes. To further corroborate
the effects recorded after NEU4 silencing in U-GSCs, we
tested the effects of a selective inhibitor of NEU4 previously
described37 and referred to as C.6 below. We first checked
the inhibition level caused by C.6 in assays of U-GSC
sialidase activity. The assay was not selective and therefore
included contributions of NEU1, NEU3, and NEU4 activities
(NEU2 expression was not detected). As shown in Figures 6a,
C.6 induced only a 16% inhibition of the total sialidase
activity, likely to be due to its selectivity for NEU4.37 Under
similar conditions, the nonspecific inhibitor, DANA (2,3-
deydro-2-deoxy-N-acetylneuraminic acid), inhibited the 37%
of total sialidase activity. We next cultivated U-GSCs in the
presence of C.6 for 4 days and recorded the effects induced
on the expression of stem-cell marker genes; C.6 treatment
of U-GSCs decreased the expression of b-catenin ( 28%),
GLI-1 ( 68%), NANOG ( 75%), and OCT-4 ( 84%)
(Figure 6b), and the amount of phospho-GSK-3b (Ser9;
66.4%; Po0.01) (Figure 6c), reproducing the same effects
seen for NEU4 silencing (Figures 3a–c). Moreover, the
proliferation and survival capabilities of U-GSCs were
impaired by C.6 treatment, similar to our observations in
iNEU4 U-GSCs (Figure 2b); after 4 days of treatment, we
observed that the initial number of U-GSCs was reduced by
44%, in contrast to non-treated U-GSCs that increased their
number by 94% in the same period of culture (Figure 6d).
In addition, we tested the effects of thymoquinone (TQ) on
U87MG cells. TQ derived from the black cumin oil has been
Figure 2 Effects of NEU4 silencing on U-GSCs survival. (a) Real-time PCR analysis of NEU4 sialidase expression in mock and iNEU4 U-GSCs. (b) Cell viability assessed
through Trypan Blue after NEU4 silencing. (c) Neurosphere assay assessed after 6 days afterNEU4 silencing. Original magnification  20 (Olympus Ix50). (d) Hoechst 33342
staining in mock and iNEU4 U-GSCs. Pseudo-colouring approach used for this image. (e) Western blot analysis of P-RB (Ser 807/811), cyclin B1, P-CDC2 (Tyr15), P-AKT
(Ser473), and active caspase 3 in mock and iNEU4 U-GSCs. b-Actin was used as loading control. Values are the mean±S.D. of four independent experiments. Significance
is based on the Student’s t-test: **Po0.01, ***Po0.001
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reported to be an agonist of NEU4 sialidase activity in live
cells.38 Consistent with this, the expression of GLI-1 and
OCT-4 increased by 775% and 700%, respectively, after
treatment with TQ (Figure 6e).
NEU4 high expression characterizes GSCs isolated from
human surgical specimens and regulates the activation
of the stemness pathways. In order to confirm our data in
cells directly isolated from patients and, therefore, to exclude
the possibility that they could be related to long-term cultures
of GBM cell lines, we assayed sialidase expression in GBM
tissues and in GSCs isolated from six human surgical
specimens, as previously described.39,40 These GBM-
derived GSCs were demonstrated to be endowed with
long-term self-renewal, high in vivo tumorigenic potential,
multipotency, and increased ability to establish and expand
GBM-like tumours in serial transplantation.39 Among siali-
dases, NEU4 expression underwent the most significant
change, increasing 40.3-fold in GBM-derived GSCs in
comparison with GBM tissues. Instead, NEU1 expression
showed a slight decrease in GSCs (1.6-fold) and NEU3
increased (13.4-fold) (Figure 7a).
In order to confirm the role of NEU4 in regulating the
‘stemness’ pathways emerged from the studies performed in
U87MG cells, we silenced NEU4 in GSCs isolated from a
surgical specimen (L0627 cells39). We achieved a 50% NEU4
silencing as mRNA. As observed for U87MG GSCs, NEU4
silencing strongly impaired LO627 GSC survival; in fact,
6 days after the end of selection mock LO627 cells began to
grow (þ 48%); 18%ofNEU4 silencing LO627-GSCs (referred
to as LO627 iNEU4) died and, after 12 days almost 52% of
LO627 iNEU4 cells died (Figure 7b). Moreover, C.6 treatment
of LO627 cells reduced the initial number by 14%, in contrast
to non-treated LO627 cells that increased their number by
100% after 4 days of culture (Figure 7c). Similar to U87MG
cells, we identified in LO627 iNEU4 cells the decrease in
mRNA expression of genes related to the SHH pathway
(SHH: 83.5%; GLI-1: 59%), to the Wnt/b catenin pathway
(b catenin: 30%; axin 2: 40%), and to ‘stemness’ transcriptional
factors and markers (NANOG: 30%; OCT-4: 40%; SOX-2:
40%; CD133: 30%) (Figure 7d). Accordingly, C.6 treatment of
LO627 cells reduced the expression of GLI-1 (37%), NANOG
(37%), OCT-4 (20%) (Figure 7e), and phospho-GSK-3b
(Ser9) content (65%; Po0.01) (Figure 7f).
Discussion
The sialidase NEU4 is the most recently identified sialidase
isoenzyme;41 its physiological role inside the cell is still largely
cryptic. Some recent papers have identified a strong involve-
ment of NEU4 in neuronal differentiation and, in particular, its
expression appeared to be elevated during the immature
stage of neuronal cells or in undifferentiated neuroblastoma
cells.22,28,29,42 The data presented here are the first to
demonstrate that NEU4 expression is high in GSCs isolated
from both GBM cell lines and patients, and that its
Figure 3 Effects of NEU4 silencing on signalling pathways related to stemness. (a) Western blot analysis of P-GSK-3b (Ser9) in mock and iNEU4 U-GSCs. b-Actin was
used as loading control. (b) Real-time PCR analysis of SHH, PTCH1, GLI-1, b catenin, axin 2, and (c) NANOG, OCT-4, SOX-2, and CD133 in mock and iNEU4 U-GSCs.
(d) Western blot analysis of EGFR in mock and iNEU4 U-GSCs. b-Actin was used as loading control. Values are the mean±S.D. of five independent experiments.
Significance is based on the Student’s t-test: *Po0.05, ***Po0.001
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upregulation appears to be intimately correlated with the
capability to form neurospheres. Cells that were not able to
form neurospheres, such as T98G cells, did not show NEU4
upregulation. In contrast, in the bulk of more differentiated
non-neurosphere GBM cells and in GBM surgical specimens,
NEU4 expression is very low. NEU4 appears to be closely
interconnected with the key pathways activated in GSCs
responsible for their stemness and self-renewal properties. In
fact, through silencing in U87MG-derived GSCs, we demon-
strated that NEU4 activity affects the activation status of GSK-
3b, inducing its inhibition (phosphorylation) whenNEU4 is fully
expressed. GSK-3b inhibition has been previously shown to
significantly reduce the stem-like CD133þ fraction of a human
GBM cell line, as well as the expression of the stem-cell
markers, SOX-2 and nestin, while, in parallel, it increased the
expression of differentiation markers, including glial fibrillary
Figure 4 Modifications induced by NEU4 silencing on U-GSC sphingolipid pattern. (a) HPTC separation of mock and iNEU4 U-GSCs gangliosides. The doublets are due
to the heterogeneity of the ceramide moiety. Solvent system: chloroform/methanol/0.2% aqueous CaCl2 60 : 40 : 9 (v/v). The image was acquired by radiochromatoscanning
(Beta Imager 2000). (b) The ganglioside content of mock and iNEU4 U-GSCs. (c) Real-time PCR analysis of GD3 synthase and (d) Sp1 expression in mock and iNEU4
U-GSCs. (e) HPTLC separation of mock and iNEU4 U-GSCs neutral sphingolipids. Solvent system: chloroform/methanol/H2O 55 : 20 : 3 (v/v). The image was acquired by
radiochromatoscanning (Beta Imager 2000). (f) The neutral sphingolipid content of mock and iNEU4 U-GSCs. The values are the mean±S.D. of five independent
experiments. Significance is based on the Student’s t-test: **Po0.01, ***Po0.001
Figure 5 Modifications induced by NEU4 silencing on U-GSC sialoglycoprotein pattern. (a) The a2-3 sialoglycoprotein profile was assessed using western blotting and
MAA (Maackia amurensis agglutinin) lectin staining of mock and iNEU4 U-GSCs. An equal content of protein was loaded in each lane. (b) Real-time PCR analysis of ST3GalIII
expression in mock and iNEU4 U-GSCs. The values are the mean±S.D. of four independent experiments. Significance is based on the Student’s t-test: **Po0.01
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acidic protein, b-tubulin III and 20, 30-cyclic nucleotide
30-phospohodiesterease.43GSK-3b inhibition by administration
of lithium or through specific inhibitors such as SB216763 has
been demonstrated to impair neurosphere formation.43 The
focal role had byGSK-3b in U-GSCs could be easily explained
by interactions with the main signalling pathways, which
sustain GSC self-renewal and propagation, SHH/GLI and
Wnt/b-catenin.44,45 Importantly, NEU4 silencing radically
changed the molecular signature of U-GSCs, decreasing the
expression of SHH, PTCH-1, and GLI-1 (key components of
the SHH pathway) of b-catenin and axin 2 (key components of
the Wnt/b-catenin pathway), and of genes regulated by them,
such as NANOG, OCT-4, and SOX-2. We found that the
expression ofCD133 decreased, possibly because this gene is
subjected to the transcriptional control ofOCT-4 and SOX-2.46
In addition, the level of EGFR was significantly reduced.
EGFR and b-catenin signalling are known to interact:
intratumoral administration of b-catenin siRNA into subcuta-
neous gliomas in nude mice has been shown to transcription-
ally downregulate EGFR.47 Therefore, we hypothesized that
the decrease of b-catenin induced byNEU4 silencing could be
responsible for the reduction in EGFR content. EGFR strongly
regulates proliferation and migration of neural stem cells.
GSCs constitutively activate EGFR, leading to the activation
of AKT. Numerous studies have revealed the crucial role of
the EGFR signalling cascade in the maintenance of GSCs,
wherein EGF is capable of promoting neurosphere formation
and self-renewal.48 Moreover, CD133 has been demon-
strated to interact with the phosphoinositide 3-kinase 85 kDa
regulatory subunit, resulting in the preferential activation of
AKT in GSCs.49 Therefore, we speculate that the decrease of
EGFR and CD133 in NEU4-silenced U-GSCs may act in
synergy to reduce AKT signalling, and thus its pro-survival
drive. The molecular revolution of U-GSCs phenotype
subsequent to NEU4 silencing involved also the expression
of GD3 synthase (ST8SiaI) that is clearly related to the
presence of ganglioside GD3. GD3 is present in neural stem
cells where it interacts with EGFR, stimulating its activation
and its downstream signalling to maintain the self-renewal
capability.16 In this study, we demonstrated that a high
expression of GD3 synthase leads to a subsequent higher
content of GD3 as a hallmark of GSCs. In normal neural stem
cells, GD3 is linked to their self-renewal.15 GD3 synthase
upregulation in GSCs appeared to be linked to the over-
expression of Sp-1 factors,50 which, in turn, could be related
also to EGFR activation.51 NEU4 silencing reverted the
upregulation of GD3 synthase, decreasing the expression of
Sp-1. We demonstrated that another feature of GSCs is the
upregulation of ST3GalIII, which is involved in the de novo
synthesis of carbohydrate antigens on different glycoproteins,
and in GSCs it could be responsible for an altered pattern of
glycosylation, already previously described.52NEU4 silencing
decreased ST3GalIII expression in U-GSCs, possibly
decreasing the expression of Sp-1 factors that have been
Figure 6 Effects induced by the chemical inhibition of NEU4 in U-GCS or activation in GBM cells. (a) In vitro sialidase activity of U-GSCs assayed towards 4-MU-NeuAc as
substrate, with the inhibitors C.6 (20 mM) and DANA (20 mM). (b) Real-time PCR analysis of b-catenin, GLI-1, NANOG, and OCT-4 expression after in vivo treatment of
U-GSCs with C.6 (0.7 mM) for 4 days. (c) Western blot analysis of P-GSK-3b (Ser9) in C.6-treated and non-treated U-GSCs. b-Actin was used as loading control. (d) Cell
viability assessed through Trypan Blue after 4 days of GSCs treatment with C.6 (0.7 mM). (e) Real-time PCR analysis of OCT-4 and GLI-1 expression in U87MG GBM cells
after 30min of TQ treatment (0.3 mM). The values are the mean±S.D. of four independent experiments. Significance is based on the Student’s t-test: **Po0.01,
***Po0.001
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demonstrated to regulate the transcription of this gene.53
In this way, NEU4 silencing changed the glycosylation pattern
of GSCs. Summing up, NEU4 silencing induced a sequence of
interrelated molecular events, summarized in Figure 8, which
significantly changed GSCs signalling and phenotype, leading
to a significant decrease of their maintenance, as recorded by
the inhibition of pro-survival pathways (AKT), the activation of
caspase-3, the increase of the pro-apoptotic molecule,
ceramide, and the decrease of the anti-apoptotic glycolipid,
LacCer. Consequently,NEU4 silencing impaired the survival of
U-GSCs inducing a block in the G2 phase and cell death.
Importantly, the effects induced by NEU4 silencing on
signalling pathways related to U-GSCs self-renewal and
propagation, and on cell proliferation were confirmed in
LO627 cells, that is, human short-term GSCs isolated from a
surgical specimen, further confirming the key role had byNEU4.
Thus, in this emerging model, NEU4 appears to be
intrinsically connected to the stem cell-like signalling of GSCs.
As a further evidence of this, the treatment of U87MG GBM
cells with TQ, an agonist of NEU4 activity,38 strongly
enhanced the expression of the stem cell-like gene expres-
sion signature. Unfortunately, it is still unclear how NEU4
could interact with GSK-3b. On the basis of these data and our
previous results that appeared to exclude the action of NEU4
on gangliosides and that identified, on the other hand, its
efficient recognition of glycoproteins,22 we strongly suspect
that also in GSCs NEU4 primarily acts on glycoproteins,
because ganglioside profile did not change accordingly to
NEU4 silencing. In fact, we recorded a decrease of GD1a and
GD3, while GM3 remained unchanged after NEU4 silencing,
instead of an increase, as expected, if these gangliosides
were really substrates of NEU4 in GSCs. These ganglioside
modifications could be related to alterations induced in the
expression of other biosynthetic enzymes such as GD3
synthase, as discussed above. Notably, inspection of the
sialo-glycoprotein pattern of NEU4-silenced GSCs showed
dramatic changes from control GSCs. We identified some
bands from 50 to 65 kDa that were more sialylated in NEU4-
silenced GSCs. These sialoglycoproteins could therefore
interact with GSK-3b, modulating its activation status based
on the level of sialylation. On the other hand, in literature,
several examples of sialoglycoproteins, including mucins,
able to interact with GSK-3 have been described.54
Finally, we tested the effects of a previously identified
specific inhibitor of NEU4 (Albohy et al.37) on both GSCs
isolated from U87MG cell lines and in LO627 cells. We found
that chemical inhibition of the enzyme resulted in similar
effects to NEU4 silencing. Treatment of GSCs with the C.6
Figure 7 Effects of NEU4 silencing and chemical inhibition in LO627 cells. (a) Real-time PCR of NEU1, NEU3, and NEU4 expression in GSCs isolated from six different
surgical specimens and in five GBM tissues. Mean values of sialidase expression in GSCs and in GBM tissues were compared. (b) Cell viability assessed through Trypan Blue
after NEU4 silencing in LO627 cells and (c) after 4 days of LO627 cells treatment with C.6 (0.7 mM). (d) Real-time analysis of SHH, PTCH1, GLI-1, b-catenin, axin 2, NANOG,
OCT-4, SOX-2, and CD133 in mock and iNEU4 LO627. (e) Real-time PCR analysis of b-catenin, GLI-1, NANOG, and OCT-4 expression after in vivo treatment of LO627 cells
with C.6 (0.7 mM) for 4 days. (f) Western blot analysis of P-GSK-3b (Ser9) in C.6-treated and non-treated LO627 cells. b-Actin was used as loading control. Significance is
based on the Student’s t-test: *Po0.05; **Po0.01, ***Po0.001
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inhibitor markedly resembled NEU4 silencing, as it reduced
the expression of b-catenin, GLI-1, NANOG, and OCT-4
stem-cell markers. Most significantly, we observed that
treatment of GSCs with the NEU4 inhibitor, C.6, impaired cell
proliferation and survival. Together, these finding confirms
that the specific inhibition of NEU4 can be explored to
suppress the growth and stem-cell phenotype of GSCs, and
suggest that this strategy could form the basis of future
therapeutic strategies for GBM.
Materials and Methods
Cell cultures. U87MG, U138MG, and T98G cells were purchased from
ECACC (Sigma Aldrich, St. Louis, MO, USA) and cultured in RPMI 1640
supplemented with 10% (v/v) fetal bovine serum and 2mM glutamine (Sigma
Aldrich). GSCs were isolated from U87MG, U138MG, and T98G cells by plating
2 103 cells/cm2 in the selective medium DMEM/F12 (Sigma Aldrich) plus
10 ng/ml basic fibroblast growth factor (Millipore, Billerica, MA, USA), 20 ng/ml EGF
(Sigma Aldrich), B27 supplement minus vitamin A (Life Technology, Carlsbad, CA,
USA), and 2mM glutamine, and culturing them for 3 weeks, at 37 1C, 5% CO2.
GSCs isolated from human post-surgical specimens and GBM tissues isolated
from patients admitted at S. Raffaele Hospital (Milan, Italy) were provided by
Dr R Galli. LO627 cells were cultured as previously described.39
NEU4 silencing in GSCs isolated from U87MG cells (U-GSCs)
and in LO627 cells. To stably silence NEU4, an miRNA targeting the human
NEU4 gene sequence was designed employing the BlockIT RNAi Designer software
(Life Technologies) and inserted into the pcDNA 6.2-GW/EmGFP-miR vector (Life
Technologies). U87-GSCs (5 105) were transfected overnight, using Lipofecta-
mine LTX and Plus Reagent (Life Technologies), according to the manufacturer’s
procedure. To stably silence NEU4 in LO627 cells, we employed the BlockIT
lentiviral PolII miR RNAi Expression System (Life Technologies) and infected cells at
an MOI of 5 according to the manufacturer’s instructions. Silenced U-GSCs and
LO627 cells were isolated after selection with 10mg/ml blasticidin for a week.
Chemical inhibition and activation of sialidase NEU4. The NEU4-
specific inhibitor, 5-acetamido-9-[4-hydroxymethyl-1,2,3-triazol-1-y1]-2,3,5,9-tetra-
deoxy-D-glycerol-D-galacto-2-nonulopyranosonic acid, referred to as compound 6
(C.6) here, was synthesized by Albohy et al.37, as previously reported. C.6
(0.7 mM) was added to 4 105 U87-GSCs or LO627 cells in the presence of
Lipofectamine LTX (Life Technologies) to allow the entry of the inhibitor inside the
Figure 8 Schematic picture of pathways regulated by NEU4 in GSCs
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cells. In parallel, control cells were treated only with Lipofectamine LTX. Cells were
collected after 4 days.
In order to stimulate NEU4 sialidase expression and enzymatic activity, 6 105
U87MG cells were treated with 0.3 mM TQ (Sigma Aldrich) for 30min at 37 1C.
Cellular death assays. To determine the cell growth and viability, 5 104
mock U-GSCs, NEU4-silenced U-GSCs, mock LO627, NEU4-silenced LO627,
C.6-treated U87-GSCs and C.6-treated LO627 cells were seeded in 96-well
culture plates. Six (for NEU4-silenced cells) or four (for C.6-treated cells) days
later, viable cells were counted with Trypan blue.
To test the clonogenic potential of mock and NEU4-silenced U-GSCs, a limiting
dilution assay was performed plating 10–20 cells/well after neurosphere dissociation
and counting cells in neurospheres newly formed after 4 days.
For Hoechst 33342 staining, 5 104 mock and NEU4-silenced U-GSCs were
washed twice with PBS and incubated for 15min with 10 mg/ml Hoechst 33342 in
the dark at room temperature. The cells were then observed using an inverted
fluorescence microscope (IX50 Olympus, Tokyo, Japan) and imaged.
Real-time PCR. Real-time PCR was performed as previously reported.19
Primer sequences were the following: NEU1: forward primer, 50-CCTGGATATTG
GCACTGAA-30, reverse primer, 50-CATCGCTGAGGAGACAGAAG-30; NEU2:
forward primer: 50-TGCGCAGAGGAGACTACGA-30, reverse primer, 50-GTCTGC
GCGTCATACAAGG-30; NEU3: forward primer, 50-GGCTTGTTTGGGTGTTTGTT-30,
reverse primer, 50-TTTTGAATTGGCTTGGGTTC-3’; NEU4: forward primer, 50-AC
CGCCGAGAGTGTTTTGG-30, reverse primer, 50-CGTGGTCATCGCTGTAGAA
GG-30; NANOG: forward primer, 50-GGTCCCAGTCAAGAAACAGA-30, reverse
primer, 50-GAGGTTCAGGATGTTGGAGA-30; OCT-4: forward primer, 50-AGGAGA
AGCTGGAGCAAAA-30, reverse primer, 50-GGCTGAATACCTTCCCAAA-30;
CD133: forward primer, 50-CTAGCCTGCGGTCATCTCTC-30, reverse primer,
50-AGGCCATCCAAATCTGTCCT-30; NES: forward primer, 50-CCAAGAACTGGC
TCAGGAAA-30, reverse primer, 50-TCTCCCTGCTCTACCACCTC-30; ST3GALIII:
forward primer, 50-CATCATCGTGGGCAATGGAG-30, reverse primer, 50-TCAAAG
CCTTTCACTGGTGC-30; b catenin: forward primer, 50-CATCATCGTGGGCAATG
GAG-30, reverse primer, 50-GCACGAACAAGCAACTGAAC-30; GLI-1: forward
primer, 50-TGAGCTGGACATGCTGGTT-30, reverse primer, 50-GATTCAGGCTCA
CGCTTCTC-30; SHH: forward primer: 50-CCCCAATTACAACCCCGACA-30,
reverse primer, 50-AGTTTCACTCCTGGCCACTG-30; PTCH1: forward primer:
50-TGCCATTTCTCGCTCTTGGT-30, reverse primer: 50-GAATTGGGATTAACGCG
GCC-30; axin 2: forward primer: 50-GGCTCCAGAAGATCACAAAG-30, reverse
primer: 50-TATGGAATTTCTTCCCCACA-30; GD3 synthase: forward primer, 50-CC
CTGAACCAGTTCGATGTT-30, reverse primer, 50-CAGCATAATTCGGCAAAGGT-30;
SOX-2: forward primer, 50-GCACATGAACGGCTGGAGCAACG-30, reverse
primer, 50-TGCTGCGAGTAGGACATGCTGTAGG-30; b actin: forward primer,
50-CGACAGGATGCAGAAGGAG-30, reverse primer, 50-ACATCTGCTGGAAGGT
GGA-30.
Western blotting. Proteins (25 mg) were separated on 10% SDS-PAGE, and
transferred onto PVDF membrane. The following antibodies were used for the
assays: anti-b actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
anti-P-AKT (Ser473), anti-EGFR, anti-cleaved caspase 3, anti-P-RB (Ser807/811),
anti-cyclin B1, P-CDC2 (Tyr15) and anti-GSK-3b (Ser9) (Cell Signaling, Danvers,
MA, USA). Blots were quantified using GS-700 calibrated densitometer and the
Quantity One software (Bio-Rad, Hercules, CA, USA).
Metabolic labelling of cell sphingolipids. Sphingolipid analysis was
carried out through cell metabolic labelling with [3-3H]sphingosine (PerkinElmer,
Waltham, MA, USA), as previously reported.20 Ganglioside and neutral
sphingolipid extracts were analysed by HPTLC carried out with the solvent
systems chloroform/methanol/0.2% CaCl2 55 : 45 : 6 (v/v) and chloroform/
methanol/water 110 : 40 : 6 (v/v), respectively.
Sialoglycoprotein analysis. Proteins (30 mg) of mock and NEU4-silenced
U-GSCs were separated on a 10% SDS-PAGE gel and transferred onto a PVDF
membrane. Sialoglycoproteins were visualized employing the DIG Glycan
Differentiation kit (Roche Applied Science, Indianapolis, IN, USA) as previously
reported.22 Densitometric analysis was performed using Quantity One software.
Sialidase activity. The sialidase activity present in the particulate fraction of
U-GSCs was assayed using 4-MU-NeuAc (4-methylumbelliferyl-N-acetylneuraminic
acid) (Sigma Aldrich) substrate, as previously reported.42 To test the inhibitory effect
of C.6 or that of DANA, the inhibitors (20mM) were added to the enzymatic mixture.
One unit of sialidase activity is defined as the amount of enzyme liberating 1mmol of
product per min.
Statistical analysis. The values are presented as the mean±S.D.
The statistical analyses were performed using Student’s t-test.
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